Establishment Labs (NASDAQ:ESTA) Posts Earnings Results, Beats Expectations By $0.07 EPS

Establishment Labs (NASDAQ:ESTA) announced its quarterly earnings results on Wednesday. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07, Briefing.com reports. The business had revenue of $37.17 million during the quarter, compared to the consensus estimate of $35.61 million. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. Establishment Labs’s revenue was down 20.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.48) earnings per share. Establishment Labs updated its FY 2024 guidance to EPS.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $56.83 on Friday. Establishment Labs has a 12 month low of $16.96 and a 12 month high of $73.00. The stock has a market capitalization of $1.56 billion, a P/E ratio of -18.69 and a beta of 1.23. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 10.26. The firm’s 50 day moving average is $50.50 and its 200 day moving average is $37.52.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ESTA shares. JPMorgan Chase & Co. raised their price target on shares of Establishment Labs from $46.00 to $53.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Citigroup lifted their target price on shares of Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Mizuho upped their target price on Establishment Labs from $50.00 to $65.00 and gave the company a “buy” rating in a report on Monday, April 1st. Finally, Stephens reiterated an “overweight” rating and set a $47.00 price target on shares of Establishment Labs in a report on Thursday, January 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Establishment Labs has a consensus rating of “Buy” and a consensus target price of $55.00.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.